Responsible for leading all R&D activities for BD’s Interventional segment including developing the current and future product portfolio. Kevin has been with BD since 2013 (Came to BD through CR Bard acquisition). Responsible for R&D for three business units; Peripheral Intervention, Surgery and Urology & Critical Care. He also sits on the RDLT and has responsibility for Innovation across BD. Experience in BD: 7 years in BD, 5 with Bard. Joined as VP of R&D for the Peripheral Intervention unit. Responsibility for developing portfolio for treating Peripheral Arterial disease and End Stage Kidney Disease. Also responsible for portfolio of biopsy products, port products, feeding products, IVC filters and CVCs. Prior to BD: 14 years in R&D / new product development, working in telecommunications and medical devices fields. Past companies include Ericsson and Medtronic. At Medtronic worked on coronary balloon angioplasty, coronary stents and coronary drug eluting stents. Also worked on AAA devices, led the development of thoracic stent grafts as well as branched devices. Led implementation of DFSS.